Page last updated: 2024-10-25

desipramine and Allodynia

desipramine has been researched along with Allodynia in 11 studies

Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
" We have used an integrative approach combining behavioural pharmacology with functional magnetic resonance imaging (fMRI) to investigate the effects of chronic treatment with the TCA desipramine, on touch-evoked pain (mechanical allodynia) and brain regional activity in the selective spinal nerve ligation (SNL) model of neuropathic pain."3.75Identification of discrete sites of action of chronic treatment with desipramine in a model of neuropathic pain. ( Chapman, V; Finn, DP; Governo, RJ; Jones, KL; Kendall, DA; Marsden, CA; Morris, PG; Prior, MJ, 2009)
"We examined if intrathecal desipramine, a selective norepinephrine reuptake inhibitor, would modulate peripheral inflammation-induced hyperalgesia."3.70Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat. ( Kawamata, M; Kawamata, T; Namiki, A; Omote, K, 1999)
"Drugs that are clinically effective (mexiletine and desipramine) or ineffective (fluoxetine) in the treatment of human neuropathic pain were evaluated for efficacy in rat models involving central sensitization (i."3.69The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization. ( Hunter, JC; Jett, MF; McGuirk, J; Waligora, D, 1997)
"Patients with neuropathic pain often experience depression and anxiety both of which are known to be temporally correlated with noradrenergic dysfunction in the locus coeruleus (LC) as pain becomes chronic."1.48The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain. ( Alba-Delgado, C; Berrocoso, E; Llorca-Torralba, M; Mico, JA, 2018)
"The management of neuropathic pain has two distinct goals-prevention of development and control of established neuropathic pain."1.43Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems. ( Deng, L; Hohmann, AG; Lee, WH; Makriyannis, A; Xu, Z, 2016)
"Ethanol-induced hyperalgesia was attenuated by systemic and local peripheral administration of inhibitors of MAO-A, reduction of norepinephrine transporter (NET) in sensory neurons and a NET inhibitor."1.35Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy. ( Alessandri-Haber, N; Bogen, O; Chen, X; Dina, OA; Green, PG; Khasar, SG; Levine, JD; Messing, RO; Reichling, DB, 2008)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's7 (63.64)29.6817
2010's2 (18.18)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zhang, P1
Terefenko, EA1
Bray, J1
Deecher, D1
Fensome, A1
Harrison, J1
Kim, C1
Koury, E1
Mark, L1
McComas, CC1
Mugford, CA1
Trybulski, EJ1
Vu, AT1
Whiteside, GT1
Mahaney, PE1
Alba-Delgado, C1
Llorca-Torralba, M1
Mico, JA1
Berrocoso, E1
Deng, L1
Lee, WH1
Xu, Z1
Makriyannis, A1
Hohmann, AG1
Dina, OA1
Khasar, SG1
Alessandri-Haber, N1
Bogen, O1
Chen, X1
Green, PG1
Reichling, DB1
Messing, RO1
Levine, JD1
Jones, KL1
Finn, DP1
Governo, RJ1
Prior, MJ1
Morris, PG1
Kendall, DA1
Marsden, CA1
Chapman, V1
Hu, B1
Doods, H1
Treede, RD1
Ceci, A1
Arsenault, A1
Sawynok, J1
Wallace, MS1
Barger, D1
Schulteis, G1
Jones, CK1
Eastwood, BJ1
Need, AB1
Shannon, HE1
Jett, MF1
McGuirk, J1
Waligora, D1
Hunter, JC1
Kawamata, T1
Omote, K1
Kawamata, M1
Namiki, A1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Preemptive Analgesia With Amitryptyline for Prevention of Post-operative Pain in Women After Total Abdominal Hysterectomy: a Randomized Clinical Trial[NCT03587025]Phase 3150 participants (Actual)Interventional2015-06-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for desipramine and Allodynia

ArticleYear
The effect of chronic oral desipramine on capsaicin-induced allodynia and hyperalgesia: a double-blinded, placebo-controlled, crossover study.
    Anesthesia and analgesia, 2002, Volume: 95, Issue:4

    Topics: Adult; Antidepressive Agents, Tricyclic; Capsaicin; Cross-Over Studies; Desipramine; Double-Blind Me

2002

Other Studies

10 other studies available for desipramine and Allodynia

ArticleYear
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2009, Sep-24, Volume: 52, Issue:18

    Topics: Administration, Oral; Animals; Behavior, Animal; Benzimidazoles; Biological Transport; Dopamine Plas

2009
The onset of treatment with the antidepressant desipramine is critical for the emotional consequences of neuropathic pain.
    Pain, 2018, Volume: 159, Issue:12

    Topics: Action Potentials; Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; CREB-Binding Pro

2018
Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.
    Pharmacological research, 2016, Volume: 114

    Topics: Animals; Antidepressive Agents, Tricyclic; Antineoplastic Agents, Phytogenic; Desipramine; Hyperalge

2016
Neurotoxic catecholamine metabolite in nociceptors contributes to painful peripheral neuropathy.
    The European journal of neuroscience, 2008, Volume: 28, Issue:6

    Topics: Alcoholic Neuropathy; Animals; Behavior, Animal; Capsaicin; Catecholamines; Clorgyline; Desipramine;

2008
Identification of discrete sites of action of chronic treatment with desipramine in a model of neuropathic pain.
    Neuropharmacology, 2009, Volume: 56, Issue:2

    Topics: Animals; Brain; Brain Mapping; Desipramine; Disease Models, Animal; Drug Administration Schedule; En

2009
Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833.
    Pain, 2009, Volume: 143, Issue:3

    Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Behavior, Animal; Depressive Disor

2009
Perisurgical amitriptyline produces a preventive effect on afferent hypersensitivity following spared nerve injury.
    Pain, 2009, Volume: 146, Issue:3

    Topics: Amitriptyline; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Brain-Derived Neurotroph

2009
Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
    Neuropharmacology, 2006, Volume: 51, Issue:7-8

    Topics: Adrenergic Uptake Inhibitors; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Stero

2006
The effects of mexiletine, desipramine and fluoxetine in rat models involving central sensitization.
    Pain, 1997, Volume: 69, Issue:1-2

    Topics: Animals; Anti-Arrhythmia Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr

1997
Analgesic effect of intrathecal desipramine on carrageenan-induced thermal hyperalgesia in the rat.
    British journal of anaesthesia, 1999, Volume: 83, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents, Tricyclic; Behavior, Animal; Carrageen

1999